{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:32:52Z","timestamp":1791484372582,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tourette syndrome (TS) is a neurodevelopmental disorder characterized by motor and phonic tics. It is a condition that affects between 0.3% and 0.7% of children, and its pathophysiology remains largely elusive. TS is associated with structural and functional alterations in corticostriatal circuits and neurochemical imbalances. Even though TS is currently incurable, there are established treatment options available, including behavioral therapy and neuroleptics. The use of cannabis-based medicine for tic management is an emerging therapeutic strategy, although its efficacy is still under investigation. It is hypothesized to interact with the endogenous cannabinoid system, but further research is required to ascertain its safety and effectiveness in TS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>In our systematic review and meta-analysis, we aim to assess the effectiveness of cannabis-based medicine in the treatment of TS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched PubMed, Cochrane, Scopus, and Web of Sciences until February 2024. We included clinical trials and cohort studies investigating the efficacy of cannabis-based medicine in the treatment of TS. Data extraction focused on baseline characteristics of the included studies and efficacy outcomes, including scores on the Yale Global Tic Severity Scale (YGTSS), Premonitory Urge for Tics Scale (PUTS), and Yale-Brown Obsessive Compulsive Scale (Y-BOCS). We conducted the meta-analysis using Review Manager version 5.4. software. We compared the measurements before and after drug intake using mean difference (MD) and 95% confidence interval (CI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 357 articles were identified for screening, with nine studies included in the systematic review and 3 in the meta-analysis. These studies involved 401 adult patients with TS treated with cannabis. YGTSS revealed a significant reduction in total scores (MD\u2009=\u2009-23.71, 95% CI [-43.86 to -3.55], <jats:italic>P<\/jats:italic>\u2009=\u20090.02), PUTS revealed a significant decrease in scores (MD\u2009=\u2009-5.36, 95% CI [-8.46 to -2.27], <jats:italic>P<\/jats:italic>\u2009=\u20090.0007), and Y-BOCS revealed no significant difference in score reduction (MD\u2009=\u2009-6.22, 95% CI [-12.68 to 0.23], <jats:italic>P<\/jats:italic>\u2009=\u20090.06).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The current study indicates promising and potentially effective outcomes with the use of cannabis-based medicine in mitigating the severity of tics and premonitory urges. However, there is a need for larger, placebo-controlled studies with more representative samples to validate these findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-024-03710-9","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T08:02:58Z","timestamp":1720598578000},"page":"1483-1493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"80","author":[{"given":"Ibrahim","family":"Serag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona Mahmoud","family":"Elsakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa Hossam El din","family":"Moawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam Tharwat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Sarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Shayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Nadim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abouzid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"3710_CR1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.12688\/f1000research.135702.1","volume":"12","author":"A Hartmann","year":"2023","unstructured":"Hartmann A, Andr\u00e9n P, Atkinson-Cl\u00e9ment C, Czernecki V, Delorme C, Monique Debes NM et al (2023) Tourette syndrome research highlights from 2022. F1000Res 12:826","journal-title":"F1000Res"},{"issue":"1","key":"3710_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/1756285610390261","volume":"4","author":"CM Eddy","year":"2011","unstructured":"Eddy CM, Rickards HE, Cavanna AE (2011) Treatment strategies for tics in Tourette syndrome. Ther Adv Neurol Disord 4(1):25\u201345","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"3710_CR3","first-page":"401","volume":"25","author":"MF Seideman","year":"2020","unstructured":"Seideman MF, Seideman TA (2020) A review of the current treatment of Tourette syndrome. J Pediatr Pharmacol Ther 25(5):401\u2013412","journal-title":"J Pediatr Pharmacol Ther"},{"key":"3710_CR4","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders [Internet]. Fifth Edition. American Psychiatric Association; 2013 [cited 2023 Dec 25]. Available from: https:\/\/doi.org\/10.1176\/appi.books.9780890425596","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"2","key":"3710_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2012.05.002","volume":"47","author":"T Knight","year":"2012","unstructured":"Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T (2012) Prevalence of tic disorders: A systematic review and meta-analysis. Pediatr Neurol 47(2):77\u201390","journal-title":"Pediatr Neurol"},{"key":"3710_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.pediatrneurol.2022.08.010","volume":"137","author":"F Jafari","year":"2022","unstructured":"Jafari F, Abbasi P, Rahmati M, Hodhodi T, Kazeminia M (2022) Systematic review and meta-analysis of Tourette syndrome prevalence; 1986 to 2022. Pediatr Neurol 137:6\u201316","journal-title":"Pediatr Neurol"},{"issue":"1","key":"3710_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/DBP.0000000000000975","volume":"43","author":"SN Charania","year":"2022","unstructured":"Charania SN, Danielson ML, Claussen AH, Lebrun-Harris LA, Kaminski JW, Bitsko RH (2022) Bullying victimization and perpetration among US children with and without Tourette syndrome. J Dev Behav Pediatr 43(1):23\u201331","journal-title":"J Dev Behav Pediatr"},{"issue":"2","key":"3710_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/mds.26089","volume":"30","author":"JM Scharf","year":"2015","unstructured":"Scharf JM, Miller LL, Gauvin CA, Alabiso J, Mathews CA, Ben-Shlomo Y (2015) Population prevalence of Tourette syndrome: A systematic review and meta-analysis. Mov Disord 30(2):221\u2013228","journal-title":"Mov Disord"},{"key":"3710_CR9","first-page":"434","volume":"10","author":"A Hartmann","year":"2021","unstructured":"Hartmann A, Szejko N, Mol Debes N, Cavanna AE, M\u00fcller-Vahl K (2021) Is Tourette syndrome a rare condition? F1000Res 10:434","journal-title":"F1000Res"},{"issue":"5","key":"3710_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11920-019-1018-z","volume":"21","author":"MA Chadehumbe","year":"2019","unstructured":"Chadehumbe MA, Brown LW (2019) Advances in the treatment of Tourette\u2019s disorder. Curr Psychiatry Rep 21(5):31","journal-title":"Curr Psychiatry Rep"},{"issue":"4","key":"3710_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/cap.2009.0118","volume":"20","author":"JF Leckman","year":"2010","unstructured":"Leckman JF, Bloch MH, Smith ME, Larabi D, Hampson M (2010) Neurobiological substrates of Tourette\u2019s disorder. J Child Adolesc Psychopharmacol 20(4):237\u2013247","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"19","key":"3710_CR12","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","volume":"92","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T, Okun MS, M\u00fcller-Vahl K, Martino D, Jankovic J, Cavanna AE et al (2019) Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92(19):896\u2013906","journal-title":"Neurology"},{"key":"3710_CR13","unstructured":"CDC. Centers for Disease Control and Prevention. 2023 [cited 2023 Dec 23]. Tourette Syndrome treatments | CDC. Available from: https:\/\/www.cdc.gov\/ncbddd\/tourette\/treatments.html"},{"issue":"4","key":"3710_CR14","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s13311-020-00914-6","volume":"17","author":"A Billnitzer","year":"2020","unstructured":"Billnitzer A, Jankovic J (2020) Current management of tics and Tourette syndrome: Behavioral, pharmacologic, and surgical treatments. Neurotherapeutics 17(4):1681\u20131693","journal-title":"Neurotherapeutics"},{"issue":"6","key":"3710_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11940-006-0036-4","volume":"8","author":"MM Qasaymeh","year":"2006","unstructured":"Qasaymeh MM, Mink JW (2006) New treatments for tic disorders. Curr Treat Options Neurol 8(6):465\u2013473","journal-title":"Curr Treat Options Neurol"},{"issue":"214","key":"3710_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115665","volume":"1","author":"MK Piscura","year":"2023","unstructured":"Piscura MK, Henderson-Redmond AN, Barnes RC, Mitra S, Guindon J, Morgan DJ (2023) Mechanisms of cannabinoid tolerance. Biochem Pharmacol 1(214):115665","journal-title":"Biochem Pharmacol"},{"key":"3710_CR17","unstructured":"Bodine M, Kemp AK. Medical cannabis use in oncology. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Mar 17]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572067\/"},{"issue":"7","key":"3710_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"HC Lu","year":"2016","unstructured":"Lu HC, Mackie K (2016) An introduction to the endogenous cannabinoid system. Biol Psychiatry 79(7):516\u2013525","journal-title":"Biol Psychiatry"},{"key":"3710_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2023.173607","volume":"230","author":"NF Parrella","year":"2023","unstructured":"Parrella NF, Hill AT, Enticott PG, Barhoun P, Bower IS, Ford TC (2023) A systematic review of cannabidiol trials in neurodevelopmental disorders. Pharmacol Biochem Behav 230:173607","journal-title":"Pharmacol Biochem Behav"},{"issue":"102","key":"3710_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.parkreldis.2022.08.014","volume":"1","author":"BM Kluger","year":"2022","unstructured":"Kluger BM, Huang AP, Miyasaki JM (2022) Cannabinoids in movement disorders. Parkinsonism Relat Disord 1(102):124\u2013130","journal-title":"Parkinsonism Relat Disord"},{"key":"3710_CR21","doi-asserted-by":"publisher","unstructured":"LJ Rice L Cannon N Dadlani MMY Cheung SL Einfeld D Efron Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: A systematic review. Eur Child Adolesc Psychiatry [Internet]. et al 2023 cited 2023 Dec 23 Available from: https:\/\/doi.org\/10.1007\/s00787-023-02169-w","DOI":"10.1007\/s00787-023-02169-w"},{"issue":"8","key":"3710_CR22","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.3390\/ijerph20085430","volume":"20","author":"D Efron","year":"2023","unstructured":"Efron D, Taylor K (2023) Medicinal cannabis for paediatric developmental, behaviouralW and mental health disorders. Int J Environ Res Public Health 20(8):5430","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"3710_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4088\/JCP.v64n0417","volume":"64","author":"KR M\u00fcller-Vahl","year":"2003","unstructured":"M\u00fcller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T et al (2003) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. J Clin Psychiatry 64(4):459\u2013465","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"3710_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1176\/ajp.156.3.495","volume":"156","author":"KR M\u00fcller-Vahl","year":"1999","unstructured":"M\u00fcller-Vahl KR, Schneider U, Kolbe H, Emrich HM (1999) Treatment of Tourette\u2019s syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156(3):495","journal-title":"Am J Psychiatry"},{"issue":"2","key":"3710_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-2002-25028","volume":"35","author":"KR M\u00fcller-Vahl","year":"2002","unstructured":"M\u00fcller-Vahl KR, Schneider U, Koblenz A, J\u00f6bges M, Kolbe H, Daldrup T et al (2002) Treatment of Tourette\u2019s syndrome with Delta 9-tetrahydrocannabinol (THC): A randomized crossover trial. Pharmacopsychiatry 35(2):57\u201361","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"3710_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/s-2001-15191","volume":"34","author":"KR M\u00fcller-Vahl","year":"2001","unstructured":"M\u00fcller-Vahl KR, Koblenz A, J\u00f6bges M, Kolbe H, Emrich HM, Schneider U (2001) Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 34(1):19\u201324","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"3710_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/0091217418791455","volume":"54","author":"EM Pichler","year":"2019","unstructured":"Pichler EM, Kawohl W, Seifritz E, Roser P (2019) Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report. Int J Psychiatry Med 54(2):150\u2013156","journal-title":"Int J Psychiatry Med"},{"key":"3710_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.parkreldis.2018.10.004","volume":"61","author":"A Thaler","year":"2019","unstructured":"Thaler A, Arad S, Schleider LBL, Knaani J, Taichman T, Giladi N et al (2019) Single center experience with medical cannabis in Gilles de la Tourette syndrome. Parkinsonism Relat Disord 61:211\u2013213","journal-title":"Parkinsonism Relat Disord"},{"key":"3710_CR29","doi-asserted-by":"crossref","unstructured":"Anis S, Zalomek C, Korczyn AD, Lassman S, Rosenberg A, Gurevich T (2023) Licensed medical cannabis use in Gilles de la Tourette syndrome: A retrospective long-term follow-up. Cannabis Cannabinoid Res\u00a0","DOI":"10.1089\/can.2022.0281"},{"issue":"5","key":"3710_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1089\/can.2022.0091","volume":"8","author":"E Abi-Jaoude","year":"2023","unstructured":"Abi-Jaoude E, Bhikram T, Parveen F, Levenbach J, Lafreniere-Roula M, Sandor P (2023) A double-blind, randomized, controlled crossover trial of cannabis in adults with Tourette syndrome. Cannabis Cannabinoid Res 8(5):835\u2013845","journal-title":"Cannabis Cannabinoid Res"},{"issue":"2","key":"3710_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11481-015-9600-6","volume":"10","author":"ME Lynch","year":"2015","unstructured":"Lynch ME, Ware MA (2015) Cannabinoids for the treatment of chronic non-cancer pain: An updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol 10(2):293\u2013301","journal-title":"J Neuroimmune Pharmacol"},{"key":"3710_CR32","unstructured":"The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research [Internet]. Washington, D.C.: National Academies Press; 2017 [cited 2024 May 14]. Available from: https:\/\/www.nap.edu\/catalog\/24625"},{"issue":"27","key":"3710_CR33","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"1","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 1(27):v119\u2013v133","journal-title":"Ann Oncol"},{"issue":"02","key":"3710_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017) Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med 13(02):307\u2013349","journal-title":"J Clin Sleep Med"},{"issue":"4","key":"3710_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11920-017-0775-9","volume":"19","author":"KA Babson","year":"2017","unstructured":"Babson KA, Sottile J, Morabito D (2017) Cannabis, cannabinoids, and sleep: A review of the literature. Curr Psychiatry Rep 19(4):23","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"3710_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/a-2256-0098","volume":"57","author":"KR M\u00fcller-Vahl","year":"2024","unstructured":"M\u00fcller-Vahl KR (2024) Cannabinoids in the treatment of selected mental illnesses: Practical approach and overview of the literature. Pharmacopsychiatry 57(3):104\u2013114","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"3710_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5603\/PJNNS.a2021.0081","volume":"56","author":"N Szejko","year":"2022","unstructured":"Szejko N, Saramak K, Lombroso A, M\u00fcller-Vahl K (2022) Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. Neurol Neurochir Pol 56(1):28\u201338","journal-title":"Neurol Neurochir Pol"},{"key":"3710_CR38","doi-asserted-by":"crossref","unstructured":"Szejko N, M\u00fcller-Vahl KR. Chapter 37 - Medical use of cannabis: applications to Tourette syndrome. In: Preedy VR, Patel VB, Martin CR, editors. Medicinal Usage of Cannabis and Cannabinoids [Internet]. Academic Press; 2023 [cited 2024 May 14]. p. 457\u201371. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780323900362000211","DOI":"10.1016\/B978-0-323-90036-2.00021-1"},{"key":"3710_CR39","doi-asserted-by":"crossref","unstructured":"Szejko N, M\u00fcller-Vahl K. Chapter Ten - Cannabinoids: Possible role in the pathophysiology and therapy of Gilles de la Tourette syndrome. In: Lavoie ME, Cavanna AE, editors. International Review of Movement Disorders [Internet]. Academic Press; 2022 [cited 2024 May 14]. p. 269\u201394. (The Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics; vol. 4). Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666787822000072","DOI":"10.1016\/bs.irmvd.2022.04.002"},{"key":"3710_CR40","doi-asserted-by":"crossref","unstructured":"Szejko N, Jakubovski E, M\u00fcller-Vahl K, Szejko N, Jakubovski E, M\u00fcller-Vahl K. Possible role of the endocannabinoid system in Tourette syndrome. In: Recent Advances in Cannabinoid Research [Internet]. IntechOpen; 2018 [cited 2024 May 14]. Available from: https:\/\/www.intechopen.com\/chapters\/62877","DOI":"10.5772\/intechopen.79895"},{"issue":"7","key":"3710_CR41","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"issue":"10","key":"3710_CR42","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol 62(10):e1-34","journal-title":"J Clin Epidemiol"},{"key":"3710_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.626459","volume":"12","author":"M Haas","year":"2021","unstructured":"Haas M, Jakubovski E, Fremer C, Dietrich A, Hoekstra PJ, J\u00e4ger B et al (2021) Yale Global Tic Severity Scale (YGTSS): Psychometric quality of the gold standard for tic assessment based on the large-scale EMTICS study. Front Psychiatry 12:626459","journal-title":"Front Psychiatry"},{"issue":"10","key":"3710_CR44","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00787-019-01450-1","volume":"29","author":"TJC Openneer","year":"2020","unstructured":"Openneer TJC, T\u00e1rnok Z, Bognar E, Benaroya-Milshtein N, Garcia-Delgar B, Morer A et al (2020) The premonitory urge for tics scale in a large sample of children and adolescents: Psychometric properties in a developmental context. An EMTICS study. Eur Child Adolesc Psychiatry 29(10):1411\u20131424","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"366","key":"3710_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 28(366):l4898","journal-title":"BMJ"},{"key":"3710_CR46","unstructured":"GA Wells, B Shea, D O\u2019Connell, J Peterson, V Welch, M Losos, et al. The Ottawa Hospital Research Institute. [cited 2024 Mar 17]. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"7","key":"3710_CR47","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1177\/21925682221110527","volume":"12","author":"JR Dettori","year":"2022","unstructured":"Dettori JR, Norvell DC, Chapman JR (2022) Fixed-effect vs random-effects models for meta-analysis: 3 points to consider. Global Spine J 12(7):1624\u20131626","journal-title":"Global Spine J"},{"key":"3710_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115135","volume":"323","author":"KR M\u00fcller-Vahl","year":"2023","unstructured":"M\u00fcller-Vahl KR, Pisarenko A, Szejko N, Haas M, Fremer C, Jakubovski E et al (2023) CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders \u2013 results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study. Psychiatry Res 323:115135","journal-title":"Psychiatry Res"},{"issue":"4","key":"3710_CR49","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1176\/appi.neuropsych.19080178","volume":"33","author":"MH Bloch","year":"2021","unstructured":"Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF (2021) A phase-2 pilot study of a therapeutic combination of \u03b4 9 -tetrahydracannabinol and palmitoylethanolamide for adults with Tourette\u2019s syndrome. JNP 33(4):328\u2013336","journal-title":"JNP"},{"issue":"4","key":"3710_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.neuropsych.16110310","volume":"29","author":"E Abi-Jaoude","year":"2017","unstructured":"Abi-Jaoude E, Chen L, Cheung P, Bhikram T, Sandor P (2017) Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome. J Neuropsychiatry Clin Neurosci 29(4):391\u2013400","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"3710_CR51","doi-asserted-by":"crossref","unstructured":"Anis S, Zalomek C, Korczyn AD, Rosenberg A, Giladi N, Gurevich T. Medical cannabis for Gilles de la Tourette syndrome: an open-label prospective study. Biagini G, editor. Behavioural Neurology. 2022 Mar 9;2022:1\u201310.","DOI":"10.1155\/2022\/5141773"},{"key":"3710_CR52","unstructured":"Barchel D, Stolar O, Ziv-Baran T, Gueta I, Berkovitch M, Kohn E, et al. Use of medical cannabis in patients with Gilles de la Tourette\u2019s syndrome in a real-world setting. Cannabis and Cannabinoid Research. 2022 Nov 7;can.2022.0112."},{"issue":"1","key":"3710_CR53","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mdc3.12696","volume":"6","author":"TL Lowe","year":"2019","unstructured":"Lowe TL, Capriotti MR, McBurnett K (2019) Long-term follow-up of patients with Tourette\u2019s syndrome. Movement Disord Clin Pract 6(1):40\u201345","journal-title":"Movement Disord Clin Pract"},{"issue":"4","key":"3710_CR54","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/can.2018.0050","volume":"4","author":"LM Milosev","year":"2019","unstructured":"Milosev LM, Psathakis N, Szejko N, Jakubovski E, M\u00fcller-Vahl KR (2019) Treatment of Gilles de la Tourette syndrome with cannabis-based medicine: Results from a retrospective analysis and online survey. Cannabis and Cannabinoid Research 4(4):265\u2013274","journal-title":"Cannabis and Cannabinoid Research"},{"issue":"2","key":"3710_CR55","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/sj.npp.1300047","volume":"28","author":"KR M\u00fcller-Vahl","year":"2003","unstructured":"M\u00fcller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U (2003) Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (\u03949-THC): No influence on neuropsychological performance. Neuropsychopharmacol 28(2):384\u2013388","journal-title":"Neuropsychopharmacol"},{"issue":"6","key":"3710_CR56","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1600-0447.1998.tb10127.x","volume":"98","author":"KR M\u00fcller-Vahl","year":"1998","unstructured":"M\u00fcller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1998) Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 98(6):502\u2013506","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"3710_CR57","first-page":"CD006565","volume":"2009","author":"A Curtis","year":"2009","unstructured":"Curtis A, Clarke CE, Rickards HE (2009) Cannabinoids for Tourette\u2019s syndrome. Cochrane Database Syst Rev 2009(4):CD006565","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3710_CR58","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1176\/ajp.150.1.98","volume":"150","author":"JF Leckman","year":"1993","unstructured":"Leckman JF, Walker DE, Cohen DJ (1993) Premonitory urges in Tourette\u2019s syndrome. Am J Psychiatry 150(1):98\u2013102","journal-title":"Am J Psychiatry"},{"issue":"4","key":"3710_CR59","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.braindev.2007.09.001","volume":"30","author":"PJ Lombroso","year":"2008","unstructured":"Lombroso PJ, Scahill L (2008) Tourette syndrome and obsessive-compulsive disorder. Brain Dev 30(4):231\u2013237","journal-title":"Brain Dev"},{"key":"3710_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.comppsych.2015.08.007","volume":"63","author":"EA Storch","year":"2015","unstructured":"Storch EA, De Nadai AS, do Ros\u00e1rio MC, Shavitt RG, Torres AR, Ferr\u00e3o YA, et al (2015) Defining clinical severity in adults with obsessive-compulsive disorder. Compr Psychiatry 63:30\u201335","journal-title":"Compr Psychiatry"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03710-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03710-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03710-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T07:23:43Z","timestamp":1726125823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03710-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3710"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03710-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"19 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}